Commentary: Continuous infusion of vancomycin in neonates: To use or not to use remains the question

Pediatric Infectious Disease Journal

Volumn 33, Issue 6, 2014, Pages 606-607

  Ward, Robert M ^a   Allegaert, Karel ^b,c   De Groot, Ronald ^d   Van Den Anker, Johannes N ^e,f,g  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^f GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^g SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN; CREATININE; ERYTHROPOIETIN; FUROSEMIDE; GENTAMICIN; NONSTEROID ANTIINFLAMMATORY AGENT; SUPEROXIDE DISMUTASE; THYMOQUINONE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; GLOMERULUS FILTRATION RATE; HUMAN; INFUSION RATE; KIDNEY DEVELOPMENT; KIDNEY TUBULE ABSORPTION; META ANALYSIS (TOPIC); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NEWBORN; NEWBORN CARE; NOTE; PLASMA CONCENTRATION-TIME CURVE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SYSTEMATIC REVIEW (TOPIC);

ANTI-BACTERIAL AGENTS; HUMANS; VANCOMYCIN;

EID: 84901500929     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000244     Document Type: Note

References (24)

1. Gwee A Cranswick N Metz D et al. Neonatal vancomycin continous infusions: still a confusion Ped Infect Dis J 2014.
2. de Hoog M Mouton JW van den Anker JN. Vancomycin: pharmacokinetics and administration regimens in neonates. Clin Pharmacokinet. 2004;43:417-440. (Pubitemid 38716502)
3. Schaible DH Rocci ML Jr. Alpert GA et al. Vancomycin pharmacokinetics in infants: relationships to indices of maturation. Pediatr Infect Dis. 1986;5:304-308. (Pubitemid 16115896)
4. Rosenblum ND. Developmental biology of the human kidney Semin Fetal Neonatal Med. 2008 13 125-132. (Pubitemid 351474625)
5. Sweeney WE Avner ED. Embryogenesis and anatomic development of the kidney. In: Polin RA Fox WW Abman SH eds. Fetal and Neonatal Physiology. Philadelphia: Elsevier Saunders; 2011:1307-1315.
6. Guignard J-P. Postnatal development of glomerular filtration rate in neonates. In: Polin RA Fox WW Abman SH eds. Fetal and Neonatal Physiology. Philadelphia: Elsevier Saunders; 2011:1339-1349.
7. De Cock RF Allegaert K Sherwin CM et al. A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates. Pharm Res. 2014;31:754-767.
8. Zhao W Kaguelidou F Biran V et al. External evaluation of population pharmacokinetic models of vanco mycin in neonates: the transferability of published models to different clinical settings. Br J Clin Pharmacol. 2012. In press.
9. Levy M Koren G Dupuis L et al. Vancomycin-induced red man syndrome. Pediatrics. 1990;86:572-580. (Pubitemid 20337152)
10. Liu C Bayer A Cosgrove SE et al.; Infectious Diseases Society of America. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18-e55.
11. Bhatt-Mehta V Schumacher RE Faix RG et al. Lack of vancomycin-associated nephrotoxicity in newborn infants: a case-control study. Pediatrics. 1999;103:e48.
12. Miner LJ Faix RG. Large vancomycin overdose in two premature infants with minimal toxicity. Am J Perinatol. 2004;21:433-438. (Pubitemid 39586779)
13. Wong-Beringer A Joo J Tse E et al. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents. 2011;37:95-101.
14. Pritchard L Baker C Leggett J et al. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med. 2010;123: 1143-1149.
15. van den Anker JN Allegaert K. Pharmacokinetics of aminoglycosides in the newborn. Curr Pharm Des. 2012;18:3114-3118.
16. Kaloyanides GJ Pastoriza-Munoz E. Aminoglycoside nephrotoxicity. Kidney Int. 1980;18:571-582. (Pubitemid 11204058)
17. Mingeot-Leclercq MP Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother. 1999;43:1003-1012. (Pubitemid 29214718)
18. Morin JP Viotte G Vandewalle A et al. Gentamicin-induced nephrotoxicity: a cell biology approach. Kidney Int. 1980;18:583-590. (Pubitemid 11204059)
19. Silverblatt FJ Kuehn C. Autorad iography of gentamicin uptake by the rat proximal tubule cell. Kidney Int. 1979;15:335-345. (Pubitemid 10219854)
20. Cowan RH Jukkola AF Arant BS Jr. Pathophysiologic evidence of gentamicin nephrotoxicity in neonatal puppies. Pediatr Res. 1980;14: 1204-1211. (Pubitemid 11226095)
21. Oktem F Arslan MK Ozguner F et al. In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: protection by erdosteine. Toxicology. 2005;215:227-233. (Pubitemid 41446325)
22. Nishino Y Takemura S Minamiyama Y et al. Targeting superoxide dismutase to renal proximal tubule cells attenuates vancomycin-induced neph rotoxicity in rats. Free Radic Res. 2003;37:373-379. (Pubitemid 36240400)
23. Cetin H Olgar S Oktem F et al. Novel evidence suggesting an anti-oxidant property for erythropoietin on vancomycin-induced nephrotoxici ty in a rat model. Clin Exp Pharmacol Physiol. 2007;34:1181-1185. (Pubitemid 47416355)
24. Basarslan F Yilmaz N Ates S et al. Protective effects of thymoquinone on vancomycin-induced nephrotoxicity in rats. Hum Exp Toxicol. 2012;31: 726-733.